DEC 05, 2022 8:00 AM PST

Favorable and Unfavorable Prognostic Genes in Human Cancers

SPONSORED BY: Atlas Antibodies

Favorable and Unfavorable Prognostic Genes in Human Cancers

Cancer is a leading cause of death worldwide, so there is an urgent need to define the molecular mechanisms driving the development and progression of individual tumors and identify a molecular signature for cancer diagnosis and prognostic evaluation.

Patient treatment and prognosis are usually defined by cancer type, size, and stage at diagnosis, using, for example, the Tumor-Node-Metastasis (TNM) staging system classification.

However, these parameters alone do not accurately predict survival in patients because there are other clinicopathological factors and molecular markers that can determine prognostic estimation, such as specific genetic mutations and comorbidities.

The essential role of biomarkers in cancer research

Identifying cancer biomarkers by immunohistochemistry (IHC) in combination with primary antibodies is a widely used strategy in cancer diagnostics, screening, and research. 

Tumor marker-specific antibodies can detect elevated quantities of tumor biomarkers in patients' blood, urine or tissue. Each tumor's biomarkers may be associated with more than one type of cancer.

A large number of molecular biomarkers, identified and validated in patients, are associated with the occurrence, progression, and prognosis of cancers. The majority of the biomarkers that have been extensively studied are proteins.

Biomarkers can be: 

  • Diagnostic: useful to determine the presence and type of cancer. 
  • Prognostic: give information on the patient's overall cancer outcome (favorable or unfavorable) with or without standard treatment.
  • Predictive: provide information about the effect of therapeutic intervention, either in terms of tumor shrinkage or survival, compared to the patient's baseline condition (the concept supporting the "personalized medicine").

The difference between these biomarkers is clearly important, but often is misinterpreted or not recognized because many markers can be both predictive and prognostic. This misinterpretation could lead to delays in treatments and shorter patient survival times.

For example, a biomarker can be an unfavorable prognostic factor but could predict favorably for response to one therapy and unfavorably for another. Furthermore, a prognostic biomarker incorrectly labeled as predictive may result in overestimating the benefits of the treatment for a single patient or a subset of the population.

Prognostic biomarkers

Identifying prognostic markers aims to define patient subpopulations with significantly different anticipated outcomes which might benefit from various therapies.

Prognostic markers can be proteins, mRNAs, miRNAs, or the gene itself. For the latter, mutations, copy number aberrations, and single nucleotide variation (SNV) could also be prognostic.

Prognostic biomarkers give information on the patient's overall cancer outcome (favorable or unfavorable) with or without standard treatment.

  • For favorable prognostic genes, higher relative expression levels at diagnosis give significantly higher overall survival for the patients.
  • For unfavorable prognostic genes, higher relative expression levels at diagnosis give significantly lower overall survival for the patients

Figure 1. Favorable and Unfavorable Prognostic Genes in Human Cancers

The schematic summarizes the number of prognostic genes with regard to 17 cancer types and their association with favorable or unfavorable clinical outcomes. The classification is based on the Pathology Atlas, part of the Human Protein Atlas (proteinatlas.org).  

Primary Antibodies for Cancer Research

The pathology Atlas to explore the expression profiles of human cancers

The Pathology Atlas is a section of the Human Protein Atlas containing information based on mRNA and protein expression data from 17 different forms of human cancer, together with millions of in-house generated immunohistochemically stained tissue sections images and more than 900,000 Kaplan-Meier plots showing the correlation between mRNA expression of each human protein gene and cancer patient survival. 

This resource allows exploration of the specific genes influencing clinical outcome for major cancers, paving the way for further in-depth studies incorporating systems-level analyses of cancer. All data presented are available in an interactive open-access database to allow for genome-wide exploration of the impact of individual proteins on clinical outcome in major human cancers.

Explore the Expression Profiles of Human Cancers

Over 21,000  Triple A PolyclonalsTM  from Atlas Antibodies helped to build the Pathology Atlas of the Human Protein Atlas.

Each antibody has been used for IHC-staining samples from 708 individuals originating from normal and cancerous human tissues. Trained pathologists have evaluated the reliability of all IHC-staining patterns.

Learn more about TripleA PolyclonalsTM

Example of Prognostic Biomarkers

Figure 2. Example of Unfavorable and Favorable Prognostic Genes.

In the Pathology Atlas a gene is considered prognostic if correlation analysis of gene expression and clinical outcome resulted in Kaplan-Meier plots with high significance (p<0.001). A gene may be prognostic in more than one cancer type.

A. JDP2 is an unfavorable prognostic gene in colorectal cancer. The patient's 5-year survival is 53% with high expression versus 64% for patients with low expression. The IHC staining using the Anti-JPD2 (HPA059511) polyclonal antibody, shows the differential expression pattern in colorectal cancer samples.

B. ABCD3 is a favorable prognostic gene in colorectal cancer. The patient's 5-year survival is 71% with high expression versus 36% for patients with low expression. The IHC staining using the Anti-ABCD3 (HPA032026) polyclonal antibody, shows the differential expression pattern in colorectal cancer samples.

C. REEP2 is an unfavorable prognostic gene in brain cancer. The patient's 3-year survival is 0% with high expression versus 10% for patients with low expression. The IHC staining using the Anti-REEP2 (HPA031813) polyclonal antibody, shows the differential expression pattern in glioma samples.

 

Download our brochure Atlas Antibodies in Colorectal Cancer Research

 

Explore primary antibodies targeting Glioma

About the Sponsor
Atlas Antibodies is a Swedish biotechnology company driving leading research worldwide through providing affinity-purified monoclonal and polyclonal antibodies, and control antigens. Our product portfolio extensively covers human proteins in cells, tissues, and organs. With our roots in the Human Protein Atlas project, an integration of antibody-based imaging, proteomics, and transcriptomics, our antibodies are selective and specific for their target proteins through our extensive validation process, ensuring reproducible results. We support you in your research. Our scientific support content and newsletter provide you with timely information about new product releases, research highlights, posters, infographics, and much more. In addition, our website contains informative whitepapers, protocols, guides, roundups of recent research papers, and blog posts. We're growing fast, having acquired two companies in 2021. UK-based Histocyte Laboratories produces high quality, reproducible cell line controls for same-slide use in histopathology available in multiple formats to suit your specific workflow and requirements. evitria is a world leading, global recombinant antibody expression service provider located in Zurich, Switzerland.
You May Also Like
JAN 09, 2023
Microbiology
Looking for custom media? We are here to help.
Looking for custom media? We are here to help.
Are you looking for custom media manufactured in a FDA compliant facility? Hardy Diagnostics is an employee owned compan ...
JAN 04, 2023
Plants & Animals
Certain fermented foods could help prevent bad breath
Certain fermented foods could help prevent bad breath
Waking up with bad breath is always a buzz kill. But what happens when bad breath persists, despite your every effort to ...
JAN 11, 2023
Microbiology
Are Shopping Malls Superspreader Sites?
Are Shopping Malls Superspreader Sites?
A new study has shown that when people go to shopping malls, they take home more than new products, and they leave more ...
JAN 18, 2023
Drug Discovery & Development
Slowing breast tumor growth with intravenous delivery of tumor suppressor genes
Slowing breast tumor growth with intravenous delivery of tumor suppressor genes
According to the American Cancer Society, breast cancer accounts for 30% of newly diagnosed invasive cancers in women. I ...
JAN 19, 2023
Cannabis Sciences
If You Consume Edibles, Here's What to Watch Out For
If You Consume Edibles, Here's What to Watch Out For
Are there any risks to consuming edibles? Here's what the experts advise you watch out for.
JAN 20, 2023
Drug Discovery & Development
Nutritional Supplement May Increase Hunger in People with Eating Disorders
Nutritional Supplement May Increase Hunger in People with Eating Disorders
Uridine, a precursor to RNA available as a nutrional supplement, may be able to treat eating disorders by increasing fee ...
Loading Comments...